01950nas a2200301   4500000000100000008004100001260001300042653001000055653002500065653001200090653001700102653001600119653001400135653001100149653002800160653001200188653000900200100001600209700001800225700001700243700001600260245007300276856004100349300001100390490000700401520122600408022001401634       1981                            d  c1981 Sep10aAdult10aAlkaline Phosphatase10aDapsone10aHaptoglobins10aHemoglobins10aHemolysis10aHumans10aL-Lactate Dehydrogenase10aleprosy10aMale1 aSritharan V1 aBharadwaj V P1 aVenkatesan K1 aGirdhar B K00aDapsone induced hypohaptoglobinemia in lepromatous leprosy patients.  uhttp://ila.ilsl.br/pdfs/v49n3a04.pdf  a307-100 v493 a<p>Dapsone has been used in various dermatological disorders and in leprosy. One of the main side effects of dapsone therapy is anemia, mostly hemolytic. We aimed at finding the effect of dapsone therapy on serum haptoglobin levels which could be an indirect evidence for intravascular hemolysis, supported by secondary investigations such as liver functions (serum lactic dehydrogenase, alkaline phosphatase, bilirubin), blood hemoglobin levels, urinary excretion of urobilinogen, and erythrocytes. As in other infectious conditions, haptoglobins were raised in untreated lepromatous cases, compared to controls (p less than 0.05). Dapsone treatment of 100 mg daily for 14 days brought down the haptoglobin level significantly as compared to the untreated cases and the controls (p less than 0.05). An elevated alkaline phosphatase and lactate dehydrogenase indicate some liver dysfunction following dapsone therapy. A significant drop in blood hemoglobin level and a concomitant increase in serum bilirubin, urinary excretion of urobilinogen, and a significant fall in the serum hemoglobin binding capacity (haptoglobin level) following treatment with dapsone are quite suggestive of mild intravascular hemolysis.</p>
  a0148-916X